FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017788398> ?p ?o ?g. }

• W2017788398 endingPage "928" @default.
• W2017788398 startingPage "919" @default.
• W2017788398 abstract "Overexpressing antiapoptotic Bcl-2 proteins to suppress apoptosis is one major mechanism via which cancer cells acquire drug resistance against cancer therapy. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4 H-chromene-3-carboxylate (HA 14-1) is one of the earliest small-molecule antagonists against antiapoptotic Bcl-2 proteins. Since its discovery, HA 14-1 has been shown to be able to synergize a variety of anticancer agents. HA 14-1 also could selectively eliminate tumor cells with elevated level of Bcl-2 protein. HA 14-1, therefore, is being intensely investigated as a potential anticancer agent. Previous reports of HA 14-1 implied that it may not be stable, raising the question of whether HA 14-1 is a suitable drug candidate. The potential stability also raised the concern about whether HA 14-1 is the bioactive species. In this report, we confirm that HA 14-1 is not stable under physiological conditions: it rapidly decomposes in RPMI cell culture medium with a half-life of 15 min. This decomposition process also generates reactive oxygen species (ROS). To identify the actual candidate(s) for the observed bioactivity of HA 14-1, we characterized the structures, quantified the amount, and evaluated the bioactivities of the decomposed products. We also used ROS scavengers to explore the function of ROS. From these studies, we established that none of the decomposition products could account for the bioactivity of HA 14-1. ROS generated during the decomposition process, however, are critical for the in vitro cytotoxicity and the apoptosis induced by HA 14-1. This study demonstrates that HA 14-1 is not stable under physiological conditions and that HA 14-1 can generate ROS through its decomposition, independent of Bcl-2 antagonism. Because of its intrinsic tendency to decompose and to generate ROS, caution should be taken in using HA 14-1 as a qualified antagonist against antiapoptotic Bcl-2 proteins." @default.
• W2017788398 created "2016-06-24" @default.
• W2017788398 creator A5005969908 @default.
• W2017788398 creator A5023569627 @default.
• W2017788398 creator A5048609901 @default.
• W2017788398 date "2007-09-18" @default.
• W2017788398 modified "2023-10-12" @default.
• W2017788398 title "Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4<i>H</i>- chromene-3-carboxylate (HA 14-1), a Prototype Small-Molecule Antagonist against Antiapoptotic Bcl-2 Proteins, Decomposes To Generate Reactive Oxygen Species That Induce Apoptosis" @default.
• W2017788398 cites W1499746632 @default.
• W2017788398 cites W1963899781 @default.
• W2017788398 cites W1975753425 @default.
• W2017788398 cites W1983823364 @default.
• W2017788398 cites W1991865867 @default.
• W2017788398 cites W1996261345 @default.
• W2017788398 cites W1999184204 @default.
• W2017788398 cites W2004896472 @default.
• W2017788398 cites W2010716981 @default.
• W2017788398 cites W2017387860 @default.
• W2017788398 cites W2018077387 @default.
• W2017788398 cites W2019539084 @default.
• W2017788398 cites W2021944232 @default.
• W2017788398 cites W2022901265 @default.
• W2017788398 cites W2023374425 @default.
• W2017788398 cites W2026211921 @default.
• W2017788398 cites W2032398079 @default.
• W2017788398 cites W2034007388 @default.
• W2017788398 cites W2036822121 @default.
• W2017788398 cites W2045200240 @default.
• W2017788398 cites W2055886738 @default.
• W2017788398 cites W2058342609 @default.
• W2017788398 cites W2065551750 @default.
• W2017788398 cites W2067323612 @default.
• W2017788398 cites W2072252062 @default.
• W2017788398 cites W2080173874 @default.
• W2017788398 cites W2085104027 @default.
• W2017788398 cites W2085419794 @default.
• W2017788398 cites W2087369364 @default.
• W2017788398 cites W2091573770 @default.
• W2017788398 cites W2093123576 @default.
• W2017788398 cites W2093496870 @default.
• W2017788398 cites W2095443553 @default.
• W2017788398 cites W2105421202 @default.
• W2017788398 cites W2109351911 @default.
• W2017788398 cites W2117049476 @default.
• W2017788398 cites W2118846850 @default.
• W2017788398 cites W2128966330 @default.
• W2017788398 cites W2139514479 @default.
• W2017788398 cites W2147259613 @default.
• W2017788398 cites W2155830864 @default.
• W2017788398 cites W2157805786 @default.
• W2017788398 cites W2162123587 @default.
• W2017788398 doi "https://doi.org/10.1021/mp7000846" @default.
• W2017788398 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17874842" @default.
• W2017788398 hasPublicationYear "2007" @default.
• W2017788398 type Work @default.
• W2017788398 sameAs 2017788398 @default.
• W2017788398 citedByCount "45" @default.
• W2017788398 countsByYear W20177883982012 @default.
• W2017788398 countsByYear W20177883982013 @default.
• W2017788398 countsByYear W20177883982015 @default.
• W2017788398 countsByYear W20177883982017 @default.
• W2017788398 countsByYear W20177883982018 @default.
• W2017788398 countsByYear W20177883982019 @default.
• W2017788398 countsByYear W20177883982020 @default.
• W2017788398 countsByYear W20177883982021 @default.
• W2017788398 countsByYear W20177883982022 @default.
• W2017788398 countsByYear W20177883982023 @default.
• W2017788398 crossrefType "journal-article" @default.
• W2017788398 hasAuthorship W2017788398A5005969908 @default.
• W2017788398 hasAuthorship W2017788398A5023569627 @default.
• W2017788398 hasAuthorship W2017788398A5048609901 @default.
• W2017788398 hasConcept C109316439 @default.
• W2017788398 hasConcept C161624437 @default.
• W2017788398 hasConcept C178790620 @default.
• W2017788398 hasConcept C185592680 @default.
• W2017788398 hasConcept C190283241 @default.
• W2017788398 hasConcept C202751555 @default.
• W2017788398 hasConcept C2778074193 @default.
• W2017788398 hasConcept C2780263894 @default.
• W2017788398 hasConcept C48349386 @default.
• W2017788398 hasConcept C55493867 @default.
• W2017788398 hasConcept C71240020 @default.
• W2017788398 hasConcept C90150868 @default.
• W2017788398 hasConceptScore W2017788398C109316439 @default.
• W2017788398 hasConceptScore W2017788398C161624437 @default.
• W2017788398 hasConceptScore W2017788398C178790620 @default.
• W2017788398 hasConceptScore W2017788398C185592680 @default.
• W2017788398 hasConceptScore W2017788398C190283241 @default.
• W2017788398 hasConceptScore W2017788398C202751555 @default.
• W2017788398 hasConceptScore W2017788398C2778074193 @default.
• W2017788398 hasConceptScore W2017788398C2780263894 @default.
• W2017788398 hasConceptScore W2017788398C48349386 @default.
• W2017788398 hasConceptScore W2017788398C55493867 @default.
• W2017788398 hasConceptScore W2017788398C71240020 @default.
• W2017788398 hasConceptScore W2017788398C90150868 @default.
• W2017788398 hasIssue "6" @default.
• W2017788398 hasLocation W20177883981 @default.
• W2017788398 hasLocation W20177883982 @default.

• next